Please use this identifier to cite or link to this item:
|Authors:||Hu, Xiu Feng;Xing, Pei Xiang|
|Affiliation:||The Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australia|
|Citation:||Current Opinion in Investigational Drugs (london, England : 2000); 6(12): 1266-71|
|Abstract:||Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.|
|Internal ID Number:||16370393|
Antineoplastic Agents.pharmacology.therapeutic use
Clinical Trials as Topic
Drug Screening Assays, Antitumor
Hodgkin Disease.drug therapy.immunology
Lymphoma, Large B-Cell, Diffuse.drug therapy.immunology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.